Research programme: neurovascular channel therapeutics - Autifony Therapeutics
Latest Information Update: 28 Oct 2025
At a glance
- Originator Autifony Therapeutics
- Class Antidementias; Small molecules; Vascular disorder therapies
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Stroke; Vascular dementia
Most Recent Events
- 28 Oct 2025 Early research in Alzheimer's disease in United Kingdom (unspecified route), before October 2025 (Autifony Therapeutics pipeline, October 2025)
- 06 Oct 2022 Early research in Stroke in United Kingdom (Autifony Therapeutics pipeline, October 2022)
- 06 Oct 2022 Early research in Vascular dementia in United Kingdom (Autifony Therapeutics pipeline, October 2022)